Charitable trust income application permits verified capital expenditure but rejects deferred pre-operative claims and requires reconsideration of con...
Reinsurance premium deductions require established regulatory breaches, while independently acquired software qualifies within the computer depreciati...
Rectification of mistake remains limited to self-evident record errors, preventing merits review through miscellaneous applications and preserving fin...
Tender creditworthiness conditions may extend to de facto Promoter Directors, with post-participation challenges generally barred absent arbitrariness...
Corporate representation in PMLA summons proceedings permitted through an authorised signatory, subject to directors' continuing cooperation and atten...
Six new Standard Input Output Norms have been fixed for Chemical and Allied Product Group A, covering Artemether PH.I/USP, Artesunate PH.I, Dihydro Artemisinin and three Doxycycline Hyclate DR tablet variants. The notified norms specify the corresponding import inputs and permitted quantities for each export product. The operative effect is to enable Regional Authorities to issue Advance Authorisations directly on the basis of these SIONs, avoiding case-by-case referral to the Norms Committee and promoting faster, more uniform approvals under the Foreign Trade Policy 2023.
Six new Standard Input Output Norms have been fixed for Chemical and Allied Product Group A, covering Artemether PH.I/USP, Artesunate PH.I, Dihydro Artemisinin and three Doxycycline Hyclate DR tablet variants. The notified norms specify the corresponding import inputs and permitted quantities for each export product. The operative effect is to enable Regional Authorities to issue Advance Authorisations directly on the basis of these SIONs, avoiding case-by-case referral to the Norms Committee and promoting faster, more uniform approvals under the Foreign Trade Policy 2023.
Note: It is a system-generated summary and is for quick reference only.